Eltrombopag

Generic Name
Eltrombopag
Brand Names
Promacta, Revolade
Drug Type
Small Molecule
Chemical Formula
C25H22N4O4
CAS Number
496775-61-2
Unique Ingredient Identifier
S56D65XJ9G
Background

Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also bee...

Indication

Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.

Associated Conditions
Chronic immune thrombocytopenia, Severe Aplastic Anemia (SAA), Thrombocytopenia
Associated Therapies
First-line Therapy
Clinical Trials
Related News

A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients

Phase 2
Terminated
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Placebo
Drug: Eltrombopag
First Posted Date
2015-05-18
Last Posted Date
2024-03-29
Lead Sponsor
Technische Universität Dresden
Target Recruit Count
132
Registration Number
NCT02446145
Locations
🇩🇪

Uniklinik RWTH Aachen, Aachen, Germany

🇩🇪

Klinikum Chemnitz GmbH, Chemnitz, Germany

🇩🇪

Marienhospital Düsseldorf GmbH, Düsseldorf, Germany

and more 12 locations

Eltrombopag for Inherited Thrombocytopenias

Phase 2
Completed
Conditions
Inherited Platelet Disorder
Interventions
Drug: Eltrombopag
First Posted Date
2015-04-21
Last Posted Date
2018-08-21
Lead Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Target Recruit Count
24
Registration Number
NCT02422394
Locations
🇮🇹

Department of Internal Medicine, Hospital of Padova, Padova, Italy

🇮🇹

Unit of Internal Medicine 3, IRCCS Policlinico San Matteo Foundation, Pavia, Italy

🇮🇹

Section of Internal and Cardiovascular Medicine, Department of Medicine, University Hospital of Perugia, Perugia, Italy

Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia

Phase 2
Completed
Conditions
Primacy Immune Thrombocytopenia
Interventions
Drug: Eltrombopag
First Posted Date
2015-03-31
Last Posted Date
2021-08-16
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
55
Registration Number
NCT02402998
Locations
🇮🇹

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia- Padiglione Marcora 2° piano, Milano, Italy

🇮🇹

Ospedale Niguarda " Ca Granda" - SC Ematologia Blocco SUD, Ponti Est, Scala E, 4° piano, Milano, Italy

🇮🇹

Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia, Roma, Italy

and more 11 locations

Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects

Phase 2
Completed
Conditions
Aplastic Anemia
Interventions
Drug: Eltrombopag
Drug: Rabbit ATG
Drug: CsA
First Posted Date
2015-03-31
Last Posted Date
2019-07-26
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
10
Registration Number
NCT02404025
Locations
🇯🇵

Novartis Investigative Site, Tokyo, Japan

A Study of Eltrombopag in Patients With CMML and Thrombocytopenia

Phase 1
Completed
Conditions
CMML
Thrombocytopenia
Interventions
Drug: eltrombopag
First Posted Date
2014-12-23
Last Posted Date
2021-04-20
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
30
Registration Number
NCT02323178
Locations
🇫🇷

CHU d'Angers, Angers, France

🇫🇷

Hôpital privé Sévigné, Cesson-Sévigné, France

🇫🇷

Centre Hospitalier de Meaux, Meaux, France

and more 23 locations

Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia

First Posted Date
2014-11-21
Last Posted Date
2018-10-23
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
100
Registration Number
NCT02298075
Locations
🇮🇹

Clinica Medica III - Padiglione ex isolamento - Azienda Ospedale Università San Martino, Genova, Italy

🇮🇹

Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova, Reggio Emilia, Italy

🇮🇹

Università Cattolica del Sacro Cuore - Policlinico A. Gemelli, Roma, Italy

and more 10 locations

Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects

First Posted Date
2014-11-02
Last Posted Date
2017-11-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
39
Registration Number
NCT02281370
Locations
🇺🇸

GSK Investigational Site, Overland Park, Kansas, United States

A Pharmacokinetic Study of Eltrombopag 50 Milligram (mg) in Healthy Volunteers Under Fasting Conditions

Phase 1
Completed
Conditions
Cirrhosis, Liver
Interventions
Drug: Eltrombopag
First Posted Date
2014-10-01
Last Posted Date
2017-11-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
26
Registration Number
NCT02254434
Locations
🇲🇽

GSK Investigational Site, Mexico City, Mexico

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

First Posted Date
2014-06-09
Last Posted Date
2017-12-12
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
356
Registration Number
NCT02158936
Locations
🇹🇷

Novartis Investigative Site, Samsun, Turkey

hATG+CsA vs hATG+CsA+Eltrombopag for SAA

Phase 3
Completed
Conditions
Severe Aplastic Anemia
Interventions
Drug: hATG
Drug: CsA
Drug: Eltrombopag
First Posted Date
2014-03-31
Last Posted Date
2020-12-22
Lead Sponsor
European Society for Blood and Marrow Transplantation
Target Recruit Count
202
Registration Number
NCT02099747
Locations
🇨🇭

University Hospital Bern, Bern, Switzerland

🇳🇱

UMCG, Groningen, Netherlands

🇨🇭

University Hospital Zürich, Zürich, Switzerland

and more 26 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy